OJSCY yields 68.19% · JNJ yields 2.13%● Live data
📍 OJSCY pulled ahead of the other in Year 1
Combined, OJSCY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OJSCY + JNJ for your $10,000?
Public Joint Stock Company Rosneft Oil Company, together with its subsidiaries, engages in the exploration, development, production, and sale of crude oil and gas. It operates in two segments, Exploration and Production; and Refining and Distribution. The company produces liquid hydrocarbons in Western and Eastern Siberia, Timan-Pechora, Ural-Volga, Southern part of European Russia, and the Russian Far East. It is also involved in producing petrochemicals products; base and industrial oils; motor and transmission oils for cars and trucks, buses, agricultural and special equipment, and railway and marine transport; special oils for the aviation industry; hydraulic, gear, turbine, compressor, transformer oils, etc.; coolants, softener oils, paraffins, etc.; and additives to fuels and oils. In addition, the company transports and exports crude oil through pipelines, and railway and mixed transportation; sells petrochemicals and liquefied petroleum gas, which include phenolic chain, aromatics, polymers, olefins, alcohols, oil refinement, fuel material, and other petrochemical products; and provides bunkering and aircraft refueling services, as well as bitumen products. Further, it operates a network of filling stations. The company was founded in 1995 and is based in Moscow, Russia. Public Joint Stock Company Rosneft Oil Company operates as a subsidiary of OJSC Rosneftegaz.
Full OJSCY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.